Journal of Thrombosis and Thrombolysis

, Volume 22, Issue 1, pp 31–38 | Cite as

Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study

  • Russell D. HullEmail author
  • Sebastian M. Schellong
  • Victor F. Tapson
  • Manuel Monreal
  • Meyer-Michel Samama
  • Alexander G. G. Turpie
  • Peter Wildgoose
  • Roger D. Yusen
Clinical Trials


Background: Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration of therapy is not currently known. The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical patients) study is designed to compare the efficacy and safety of extended-duration thromboprophylaxis using enoxaparin with the standard regimen of enoxaparin in acutely ill medical patients with recent reduced mobility.

Methods: All enrolled acutely ill medical patients receive enoxaparin 40 mg subcutaneously once daily for 10 ± 4 days. Eligible patients are then randomized in a blinded manner to receive either extended-duration thromboprophylaxis with enoxaparin 40 mg subcutaneously once daily or placebo subcutaneously once daily for an additional 28 ± 4 days. The primary efficacy endpoint is the incidence of VTE during the 28 ± 4 days after randomization. This study utilizes a standardized bilateral compression ultrasonography examination protocol that consists of an intensive interrogation of the deep veins of the lower extremities for proximal deep-vein thrombosis. The secondary efficacy endpoints are the rate of symptomatic VTE during the 3 months after randomization and mortality at 3 and 6 months after enrollment. The primary safety endpoint is the incidence of major hemorrhagic complications during the 28 ± 4 days after randomization.

Results: To date, 3,983 patients, with a broad range of medical conditions, have been included in the study. Almost one third of the enrolled patients with reduced mobility are acutely ill due to respiratory insufficiency and one third have infectious diseases.

Conclusions: The EXCLAIM study is designed to show the efficacy and safety of extended-duration thromboprophylaxis using enoxaparin in acutely ill medical patients with recent reduced mobility, which may potentially lead to a reduction in the incidence of late VTE events in these patients.

Abbreviated abstract

The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical patients) study, involving 4,726 acutely ill medical patients with recent reduced mobility, is designed to compare the efficacy and safety of extended-duration thromboprophylaxis using 40 mg once daily enoxaparin (38 ± 4 days) with the standard regimen for enoxaparin (40 mg once daily for 10 ± 4 days). The objective of this study is to demonstrate that the extended-duration enoxaparin regimen is an effective and safe thromboprophylaxis regimen out of hospital.


Medical patients Low-molecular-weight heparin Prophylaxis Venous thromboembolism 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Geerts WH, Pineo GF, Heit JA, et al (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S–400SGoogle Scholar
  2. 2.
    Nicolaides AN, Breddin HK, Fareed J, et al (2001) Prevention of venous thromboembolism. International Consensus Statement Guidelines compiled in accordance with the scientific evidence. Int Angiol 20:1–37PubMedCrossRefGoogle Scholar
  3. 3.
    Heit JA, O’Fallon WM, Petterson TM, et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. A population-based study. Arch Intern Med 162:1245–1248PubMedCrossRefGoogle Scholar
  4. 4.
    Lindblad B, Sternby NH, Bergqvist D (1991) Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 302:709–711PubMedCrossRefGoogle Scholar
  5. 5.
    Sandler DA, Martin JF (1989) Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis? J R Soc Med 82:203–205Google Scholar
  6. 6.
    Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV (1996) The changing pattern of venous thromboembolic disease. Haemostasis 26:65–71Google Scholar
  7. 7.
    Baglin TP, White K, Charles A (1997) Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 50:609–610PubMedGoogle Scholar
  8. 8.
    Hauch O, Jorgensen LN, Khattar SC, et al (1990) Fatal pulmonary embolism associated with surgery. An autopsy study. Acta Chir Scand 156:747–749PubMedGoogle Scholar
  9. 9.
    Samama M-M (2000) An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 160:3415–3420PubMedCrossRefGoogle Scholar
  10. 10.
    Samama MM, Dahl OE, Quinlan DJ, Mismetti P, Rosencher N (2003) Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica 88:1410–1421PubMedGoogle Scholar
  11. 11.
    Heit JA, Silverstein MD, Mohr DN, et al (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86:452–463PubMedGoogle Scholar
  12. 12.
    Alikhan R, Cohen AT, Combe S, et al (2004) Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 164:963–968PubMedCrossRefGoogle Scholar
  13. 13.
    Goodstein F, Stampfer MJ, Goldhaber SZ, et al (1996) Prospective study of exogenous hormones and risk of PE in women. Lancet 348:983–987CrossRefGoogle Scholar
  14. 14.
    Grady D, Wenger NK, Herrington D, et al (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen-progestin Replacement Study. Ann Intern Med 132:689–696PubMedGoogle Scholar
  15. 15.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.Google Scholar
  16. 16.
    Oger E, Leroyer C, Le Moigne E, et al (1997) The value of a risk factor analysis in clinically suspected deep vein thrombosis. Respiration 64:326–330PubMedCrossRefGoogle Scholar
  17. 17.
    Anderson FA Jr, Wheeler HB, Goldberg RJ, et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938PubMedCrossRefGoogle Scholar
  18. 18.
    Bonifacj C, Quere I, Dupuy C, et al (1997) [Case control studies of the risk factors for deep-vein thrombosis in an adult population hospitalized in internal medicine]. Rev Epidemiol Sante Publique 45:465–473PubMedGoogle Scholar
  19. 19.
    Howell MD, Geraci JM, Knowlton AA (2001) Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J Clin Epidemiol 54:810–816PubMedCrossRefGoogle Scholar
  20. 20.
    Cogo A, Bernardi E, Prandoni P, et al (1994) Acquired risk factors for DVT in symptomatic outpatients. Arch Intern Med 154:164–168PubMedCrossRefGoogle Scholar
  21. 21.
    Quere I, Perneger TV, Zittoun J, et al (2002) Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 359:747–752PubMedCrossRefGoogle Scholar
  22. 22.
    Samama MM, Cohen AT, Darmon J-Y, et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341:793–800PubMedCrossRefGoogle Scholar
  23. 23.
    Leizorovicz A, Cohen AT, Turpie AGG, et al (2004) Randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879PubMedCrossRefGoogle Scholar
  24. 24.
    Cohen AT, Davidson BL, Gallus AS, et al (2003) Fondaparinux for the prevention of VTE in acutely ill medical patients [abstract]. Blood 102:15a [Abstract number 42]Google Scholar
  25. 25.
    Tapson VF, Decousus H, Piovella F, et al (2003) for the IMPROVE investigators. A multinational observational cohort study in acutely ill medical patients of practices in prevention of venous thromboembolism: findings of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) [abstract]. Blood 102:321a [Abstract number 1154]Google Scholar
  26. 26.
    Hull RD, Pineo GF (1999) Extended prophylaxis against venous thromboembolism following total hip and knee replacement. Haemostasis 29 (Suppl 1):23–31PubMedCrossRefGoogle Scholar
  27. 27.
    Eikelboom JW, Quinlan DJ, Douketis JD (1999) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9–15Google Scholar
  28. 28.
    Hull RD, Pineo GF, Stein PD, et al (2001) Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep vein thrombosis after elective hip arthroplasty: a systematic review. Ann Intern Med 135:858–869PubMedGoogle Scholar
  29. 29.
    Bergqvist D, Agnelli G, Cohen AT, et al (2002) for the ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975–980PubMedCrossRefGoogle Scholar
  30. 30.
    Moher D, Schulz KF, Altman DG (2001) CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134:657–662Google Scholar
  31. 31.
    Ioannidis JP, Evans SJ, Gøtzsche PC, et al (2004) CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141:781–788Google Scholar
  32. 32.
    Kearon C, Julian JA, Newman TE, Ginsberg JS (1998) Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 128:663–677PubMedGoogle Scholar
  33. 33.
    Schellong SM, Schwarz T, Pudollek T, Schmidt B, Schroeder HE (2001) Complete compression ultrasound for the diagnosis of proximal and distal deep venous thrombosis—a retrospective outcome study. Vasa 30:253–257PubMedCrossRefGoogle Scholar
  34. 34.
    Schellong SM, Schwarz T, Halbritter K, et al (2003) Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost 89:228–234PubMedGoogle Scholar
  35. 35.
    Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW (2003) THE-PRINCE study group. A randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145:614–621PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  • Russell D. Hull
    • 1
    Email author
  • Sebastian M. Schellong
    • 2
  • Victor F. Tapson
    • 3
  • Manuel Monreal
    • 4
  • Meyer-Michel Samama
    • 5
  • Alexander G. G. Turpie
    • 6
  • Peter Wildgoose
    • 7
  • Roger D. Yusen
    • 8
  1. 1.Thrombosis Research unit, Foothills HospitalUniversity of CalgaryCalgaryCanada
  2. 2.Universitätsklinikum Carl Gustav Carus Medizinische Klinik und Poliklinik IIIDresdenGermany
  3. 3.Duke University Medical CenterDurhamUSA
  4. 4.Hospital Germans Trias i PujolBarcelonaSpain
  5. 5.Servie d’Hematologie BiologiqueParisFrance
  6. 6.HHSC McMaster ClinicMcMaster UniversityHamiltonCanada
  7. 7.Sanofi-AventisBridgewaterUSA
  8. 8.Washington University School of MedicineSt. LouisUSA

Personalised recommendations